EN | UA
EN | UA

Help Support

Back

Filgotinib effect on patients with active psoriatic arthritis

Filgotinib effect on patients with active psoriatic arthritis Filgotinib effect on patients with active psoriatic arthritis
Filgotinib effect on patients with active psoriatic arthritis Filgotinib effect on patients with active psoriatic arthritis

What's new?

With the rapid onset of action, filgotinib presents significant improvements in the condition of patients suffered from active psoriatic arthritis.

Evident from the EQUATOR trial, “the psoriatic arthritis treatment with filgotinib shows considerable rectifications in psoriasis, enthesitis, and peripheral arthritis.” The trial involved a total of 191 patients with active moderate-to-severe psoriatic arthritis from 25 places in seven countries.

These patients showed no response against at least one csDMARD (one conventional synthetic disease-modifying anti-rheumatic drug) and the uptake of that DMARD was continued throughout the analysis, if the patients obtained this treatment for 12 weeks before screening. Afterwards, they were on a stable dose for approximately four weeks prior to baseline. Further, the patients obtaining 20% improvements in ACR20 (American College of Rheumatology response criteria) at week 16 was considered as the major endpoint of the analysis.

The major endpoint noticed in 80% of patients from filgotinib group and 33% of placebo group. The most common side effects that noticed in both groups were headache and nasopharyngitis. There was one treatment-emergent adverse effect also found in the patients of both groups. Regarding safety, no new data was detected. Overall, this JAK1 inhibition shows significant better overall psoriatic arthritis disease control.

Source:

The Lancet

Article:

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Authors:

Philip Mease et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: